The first clinically approved BH3-mimetic, ABT199 (venetoclax), specifically targets BCL-2 and is currently used in chronic lymphocytic leukemia (CLL) and AML, which are often dependent upon BCL-2 for cancer cell survival [102–104]. This evidence concerns the gene BCL2 and cancer.